Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Cash & Equivalents (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Cash & Equivalents for 5 consecutive years, with $65.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 46.5% to $65.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $65.7 million, a 46.5% decrease, with the full-year FY2024 number at $111.0 million, down 17.38% from a year prior.
  • Cash & Equivalents was $65.7 million for Q3 2025 at Werewolf Therapeutics, down from $77.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $183.2 million in Q2 2021 to a low of $65.7 million in Q3 2025.
  • A 5-year average of $128.9 million and a median of $135.3 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 69.87% in 2022, then plummeted 46.5% in 2025.
  • Werewolf Therapeutics' Cash & Equivalents stood at $157.5 million in 2021, then decreased by 17.91% to $129.3 million in 2022, then grew by 3.89% to $134.3 million in 2023, then dropped by 17.38% to $111.0 million in 2024, then tumbled by 40.8% to $65.7 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Cash & Equivalents are $65.7 million (Q3 2025), $77.6 million (Q2 2025), and $92.0 million (Q1 2025).